{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:20:05Z","timestamp":1785284405927,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>From 2019 to 2021, Rwandan residents of the border with the Democratic Republic of the Congo were offered the Ad26.ZEBOV (adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein) and MVA-BN-Filo (modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola, Sudan, Marburg, and nucleoprotein from Tai Forest viruses) Ebola vaccine regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Nonpregnant persons aged \u22652 years were eligible. Unsolicited adverse events (UAEs) were reported through phone calls or visits, and serious adverse events (SAEs) were recorded per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following Ad26.ZEBOV, UAEs were reported by 0.68% of 216 113 vaccinees and were more common in younger children (aged 2\u20138 years, 1.2%) compared with older children (aged 9\u201317 years, 0.4%) and adults (aged \u226518 years, 0.7%). Fever and headache were the most reported symptoms. All 17 SAEs related to vaccine were in children aged 2\u20138 years (10 postvaccination febrile convulsions \u00b1 gastroenteritis and 7 fever and\/or gastroenteritis). The incidence of febrile seizures was 8 of 26 062 (0.031%) prior to initiation of routine acetaminophen in December 2020 and 2 of 15 897 (0.013%) thereafter. Nonobstetric SAEs were similar in males and females. All 20 deaths were unrelated to vaccination. Young girls and adult women with UAEs were less likely to receive the second dose than those without UAEs. Seven unrelated SAEs occurred in 203 267 MVA-BN-Filo recipients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Postvaccination febrile convulsions in young children were rare but not previously described after Ad26.ZEBOV and were reduced with routine acetaminophen. The regimen was otherwise safe and well-tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac283","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T15:07:11Z","timestamp":1656688031000},"page":"268-277","source":"Crossref","is-referenced-by-count":26,"title":["Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign"],"prefix":"10.1093","volume":"227","author":[{"given":"Julien","family":"Nyombayire","sequence":"first","affiliation":[{"name":"Center for Family Health Research , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Ingabire","sequence":"additional","affiliation":[{"name":"Center for Family Health Research , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Magod","sequence":"additional","affiliation":[{"name":"Rwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Mazzei","sequence":"additional","affiliation":[{"name":"Center for Family Health Research , Kigali , Rwanda"},{"name":"Department of Pathology, School of Medicine, Emory University, Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Mazarati","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Noben","sequence":"additional","affiliation":[{"name":"Janssen Global Public Health R&D , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Katwere","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Parker","sequence":"additional","affiliation":[{"name":"Rwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Nsanzimana","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Wall","sequence":"additional","affiliation":[{"name":"Rwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"},{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sayinzoga","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tichacek","sequence":"additional","affiliation":[{"name":"Rwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Hammoud","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[{"name":"Independent Consultant , Wellington , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Allen","sequence":"additional","affiliation":[{"name":"Rwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Karita","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Emory University, Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"2023011117473209400_jiac283-B1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"2023011117473209400_jiac283-B2","author":"M\u00e9decins Sans Fronti\u00e8res","year":"2021"},{"key":"2023011117473209400_jiac283-B3","author":"World Health Organization"},{"key":"2023011117473209400_jiac283-B4","author":"World Health Organization"},{"key":"2023011117473209400_jiac283-B5","author":"KTPress"},{"key":"2023011117473209400_jiac283-B6"},{"key":"2023011117473209400_jiac283-B7","author":"Johnson & Johnson"},{"key":"2023011117473209400_jiac283-B8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J Infect Dis"},{"key":"2023011117473209400_jiac283-B9","article-title":"O1059 safety and immunogenicity of a 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase III clinical trial in Sierra Leone","author":"Leigh BI","year":"2019","journal-title":"29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 13\u201316 April"},{"key":"2023011117473209400_jiac283-B10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"2023011117473209400_jiac283-B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J Infect Dis"},{"key":"2023011117473209400_jiac283-B12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023011117473209400_jiac283-B13","article-title":"P0399 safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe (EBOVAC2)","volume-title":"29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, the Netherlands, 13\u201316 April","author":"Thiebaut","year":"2019"},{"key":"2023011117473209400_jiac283-B14","doi-asserted-by":"crossref","first-page":"1829829","DOI":"10.1080\/16549716.2020.1829829","article-title":"Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda","volume":"13","author":"Kitonsa","year":"2020","journal-title":"Glob Health Action"},{"key":"2023011117473209400_jiac283-B15","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine against Ebola in African children and adolescents","author":"Afolabi"},{"key":"2023011117473209400_jiac283-B16","year":"2021"},{"key":"2023011117473209400_jiac283-B17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/tmi.13548","article-title":"Febrile seizures in an urban Tanzanian population: lessons learned from a community-based random cluster survey","volume":"26","author":"Stelzle","year":"2021","journal-title":"Trop Med Int Health"},{"key":"2023011117473209400_jiac283-B18","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010\u20132011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"key":"2023011117473209400_jiac283-B19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"key":"2023011117473209400_jiac283-B20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.3129","article-title":"Common variants associated with general and MMR vaccine-related febrile seizures","volume":"46","author":"Feenstra","year":"2014","journal-title":"Nat Genet"},{"key":"2023011117473209400_jiac283-B21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00006454-200208000-00014","article-title":"Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age","volume":"21","author":"Greenberg","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2023011117473209400_jiac283-B22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2013.12.011","article-title":"Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR + V vaccination","volume":"32","author":"Schink","year":"2014","journal-title":"Vaccine"},{"key":"2023011117473209400_jiac283-B23","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"key":"2023011117473209400_jiac283-B24","first-page":"81","article-title":"Adverse events following immunization reporting and impact on immunization services in informal settlements in Nairobi, Kenya: a prospective mixed-methods study","volume":"40","author":"Malande","year":"2021","journal-title":"Pan Afr Med J"},{"issue":"Suppl 2","key":"2023011117473209400_jiac283-B25","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1016\/j.vaccine.2011.12.112","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30","author":"Ouandaogo","year":"2012","journal-title":"Vaccine"},{"key":"2023011117473209400_jiac283-B26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s13063-022-06360-3","article-title":"Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial","volume":"23","author":"Karita E, Nyombayire J, Ingabire R, et al","year":"2022","journal-title":"Trials"},{"key":"2023011117473209400_jiac283-B27","author":"World Health Organization"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac283\/45029354\/jiac283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/2\/268\/48618106\/jiac283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/2\/268\/48618106\/jiac283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T18:26:17Z","timestamp":1673461577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/2\/268\/6625827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,1]]},"published-print":{"date-parts":[[2023,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac283","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,15]]},"published":{"date-parts":[[2022,7,1]]}}}